- Home
- NVG vs VCYT Comparison
NVG vs VCYT Comparison
Compare NVG & VCYT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NVG
- VCYT
- Stock Information
- Founded
- NVG 1999
- VCYT 2006
- Country
- NVG United States
- VCYT United States
- Employees
- NVG N/A
- VCYT N/A
- Industry
- NVG Investment Managers
- VCYT Medical Specialities
- Sector
- NVG Finance
- VCYT Health Care
- Exchange
- NVG Nasdaq
- VCYT Nasdaq
- Market Cap
- NVG 2.6B
- VCYT 2.6B
- IPO Year
- NVG N/A
- VCYT 2013
- Fundamental
- Price
- NVG $12.28
- VCYT $36.00
- Analyst Decision
- NVG
- VCYT Buy
- Analyst Count
- NVG 0
- VCYT 9
- Target Price
- NVG N/A
- VCYT $39.89
- AVG Volume (30 Days)
- NVG 568.8K
- VCYT 956.5K
- Earning Date
- NVG 01-01-0001
- VCYT 11-05-2025
- Dividend Yield
- NVG 4.65%
- VCYT N/A
- EPS Growth
- NVG N/A
- VCYT N/A
- EPS
- NVG N/A
- VCYT 0.34
- Revenue
- NVG N/A
- VCYT $479,129,000.00
- Revenue This Year
- NVG N/A
- VCYT $14.28
- Revenue Next Year
- NVG N/A
- VCYT $9.83
- P/E Ratio
- NVG N/A
- VCYT $107.24
- Revenue Growth
- NVG N/A
- VCYT 19.91
- 52 Week Low
- NVG $9.68
- VCYT $22.61
- 52 Week High
- NVG $12.21
- VCYT $47.32
- Technical
- Relative Strength Index (RSI)
- NVG 57.06
- VCYT 67.93
- Support Level
- NVG $12.24
- VCYT $31.81
- Resistance Level
- NVG $12.44
- VCYT $34.89
- Average True Range (ATR)
- NVG 0.10
- VCYT 1.43
- MACD
- NVG -0.01
- VCYT 0.16
- Stochastic Oscillator
- NVG 50.00
- VCYT 84.60
About NVG Nuveen AMT-Free Municipal Credit Income Fund
Nuveen AMT-Free Municipal Credit Income Fund is a diversified, closed-end management investment company. Its objective is to provide current income exempt from regular federal income tax and federal alternative minimum tax applicable to individuals and enhance portfolio value relative to the municipal bond market by investing in tax-exempt municipal bonds that the investment adviser believes are underrated or undervalued or represent undervalued municipal market sectors.
About VCYT Veracyte Inc.
Veracyte Inc is a genomic diagnostics company. The group empowers clinicians with the insights necessary to guide and assure patients at pivotal moments in the race to diagnose and treat cancer. It offers tests for prostate cancer (Decipher Prostate), thyroid cancer (Afirma), breast cancer (Prosigna), and bladder cancer (Decipher Bladder). In addition, its Percepta Nasal Swab test is being run in CLIA labs in support of clinical studies.